Streetbeat News

Stock Prices

MAIA

MAIA Biotechnology Inc (NASDAQ:MAIA) stock dropped 20.97% to $1.47 after announcing a registered direct offering of approximately 2.4 million shares at $1.65 each. The offering includes unregistered warrants, exercisable at $1.86 per share after six months, and is expected to close around November 17. H.C. Wainwright & Co. is the exclusive placement agent. The proceeds, estimated at $4 million, will fund general operations and R&D in cancer therapy. MAIA's 52-week range is $1.42 to $5.22.

Portfolio Pulse from Henry Khederian

November 15, 2023 | 3:42 pm

JD

JD.com's stock price has increased following the release of their mixed Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 3:42 pm

VEON

VEON Ltd. (NASDAQ:VEON) has appointed Michael R. Pompeo as an independent non-executive director of Kyivstar's Board and CEO Kaan Terzioglu as Chair of the same board. This follows VEON's challenge to a freeze on its corporate rights in Ukraine and its commitment to invest $600 million in the country. VEON has also completed the sale of its Russian subsidiary. Shares of VEON are up 3.16% to $20.22.

Portfolio Pulse from Nabaparna Bhattacharya

November 15, 2023 | 3:42 pm

STRO

Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Sutro Biopharma (NASDAQ:STRO) but reduced the price target from $18 to $12.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 3:38 pm

NU

Nu Holdings shares are trading lower following the report of their Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 3:38 pm

BHVN

Piper Sandler analyst Christopher Raymond has maintained an Overweight rating on Biohaven (NYSE:BHVN) and increased the price target from $29 to $36, as reported on November 14, 2023.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 3:36 pm

GMDA

Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Gamida Cell (NASDAQ:GMDA) but reduced the price target from $5 to $2 as reported on November 14, 2023.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 3:34 pm

TMO

Thermo Fisher Scientific has authorized a new $4 billion share repurchase program, which has led to an increase in its stock price.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 3:33 pm

GMDA

Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Gamida Cell (NASDAQ:GMDA) but reduced the price target from $5 to $2.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 3:33 pm

ORCL

Over the past 10 years, Oracle (NYSE:ORCL) has delivered an average annual return of 12.72%, outperforming the market. A $1000 investment in ORCL a decade ago would be worth $3,294.02 today. Oracle's market cap stands at $318.45 billion.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 3:30 pm